Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Buys $526,121.52 in Stock

Ventyx Biosciences, Inc. (NASDAQ:VTYX) CEO Raju Mohan purchased 261,752 shares of the firm’s stock in a transaction on Monday, November 25th. The stock was bought at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares in the company, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Raju Mohan also recently made the following trade(s):

• On Friday, November 22nd, Raju Mohan bought 238,248 shares of Ventyx Biosciences stock. The stock was purchased at an average price of $1.83 per share, for a total transaction of $435,993.84.

Ventyx Biosciences Trading Up 4.3 %

Shares of VTYX opened at $2.65 on Thursday. The company’s fifty day simple moving average is $2.19 and its 200-day simple moving average is $2.62. The company has a market cap of $187.38 million, a P/E ratio of -1.12 and a beta of 0.37. Ventyx Biosciences, Inc. has a twelve month low of $1.67 and a twelve month high of $11.48.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Canaccord Genuity Group reduced their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Oppenheimer reaffirmed an “outperform” rating and set a $9.00 price target (down previously from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. HC Wainwright reissued a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research note on Monday, November 11th. Finally, Wells Fargo & Company decreased their target price on shares of Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research report on Monday, August 12th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Trading of Ventyx Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC grew its stake in shares of Ventyx Biosciences by 8,483.8% during the first quarter. Ikarian Capital LLC now owns 507,647 shares of the company’s stock valued at $2,792,000 after buying an additional 501,733 shares during the last quarter. Farallon Capital Management LLC bought a new position in Ventyx Biosciences in the 1st quarter valued at $17,435,000. Opaleye Management Inc. increased its stake in Ventyx Biosciences by 12.7% in the first quarter. Opaleye Management Inc. now owns 1,285,000 shares of the company’s stock worth $7,068,000 after purchasing an additional 145,000 shares during the period. SG Americas Securities LLC bought a new stake in shares of Ventyx Biosciences during the second quarter worth $32,000. Finally, Bank of New York Mellon Corp boosted its stake in shares of Ventyx Biosciences by 58.4% during the second quarter. Bank of New York Mellon Corp now owns 230,593 shares of the company’s stock valued at $533,000 after purchasing an additional 84,984 shares during the period. 97.88% of the stock is owned by hedge funds and other institutional investors.

About Ventyx Biosciences

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.